Seeking Alpha

BMO Capital weighs in on the FDA rejection of Amgen's (AMGN -1.3%) Xgeva cancer drug, saying...

BMO Capital weighs in on the FDA rejection of Amgen's (AMGN -1.3%) Xgeva cancer drug, saying that if the firm fails to ultimately win approval for use of the drug it could lose revenue of as much as $1B.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)